1-4 of 4
Vishnu Mishra, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Francine M. Foss, MD, Won-Seog Kim, MD PhD, Eric Jacobsen, MD, Maria de Fatima De La Cruz, MD, Dolores Caballero, MD PhD, Ranjana H Advani, MD, Jose Maria Roncero, MD, Raquel de Oña, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, Maria Jose Terol, Eva Domingo-Domenech, MD, Miguel A. Piris, Marta Rodriguez, James Bolognese, PhD, Linda Kessler, BA, Vishnu Mishra, PhD, Robert Curry, BA, MBA, Michael Kurman, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 468.
https://doi.org/10.1182/blood-2019-128513
Published: 2019
Journal Articles

Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients

Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Vishnu Mishra, PhD, Matthew R Janes, PhD, Linda Kessler, BA
Journal: Blood
Blood (2018) 132 (Supplement 1): 5349.
https://doi.org/10.1182/blood-2018-99-116969
Published: 2018
Journal Articles

Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)

Mrinal M. Patnaik, MDMBBS, David A Sallman, MD, Mikkael A. Sekeres, MD MS, Selina Luger, MD FRCPC, Rafael Bejar, MD PhD, Gabriela S. Hobbs, MD, Amy E. DeZern, MD, James Bolognese, PhD, Mary Traynor, RN, Vishnu Mishra, PhD, David Wages, MD PhD, Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Eric Padron, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2963.
https://doi.org/10.1182/blood.V130.Suppl_1.2963.2963
Published: 2017
Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E Witzig, MD, Lubomir Sokol, MD PhD, Eric Jacobsen, MD, Ranjana H. Advani, MD, Francine M Foss, MD, Rufino Mondejar, PhD, Miguel Angel Piris, PhDMD, James Bolognese, PhD, Francis Burrows, PhD, Linda Kessler, BA, Karen Bracken, MHS, Vishnu Mishra, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2788.
https://doi.org/10.1182/blood.V130.Suppl_1.2788.2788
Published: 2017